


The following listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Amended): A compound of the formula:




wherein X is selected from the group consisting of O and S; wherein A<sub>1</sub> and A<sub>2</sub> are individually selected from the group consisting of O, S and NH;

wherein G<sub>1</sub> and G<sub>3</sub> are C<sub>1-4</sub> alkyl chains;

wherein G<sub>5</sub> is a C<sub>0-4</sub> alkyl chain; and

wherein G<sub>2</sub> is H or ~~selected from the group consisting of:~~




wherein A<sub>3</sub> is NH and A<sub>4</sub> is NH<sub>2</sub> or

~~-NH-G<sub>2</sub> forms a urea moiety are individually selected from the group consisting of O, N, and S, wherein the valencies of each O, N or S are adjusted by adding a H if needed;~~

wherein G<sub>4</sub> is a C<sub>5-8</sub> aryl, a C<sub>5-8</sub> arylsulfonylamino, an C<sub>5-8</sub> arylamino; and

wherein G<sub>6</sub> and G<sub>7</sub> are individually selected from the group consisting of H, F, Cl, I, Br and a C<sub>1-4</sub> alkyl.

2. (Original): The compound of claim 1, wherein X is S.
3. (Original): The compound of claim 1, wherein X is O.
4. (Previously Amended): The compound of claim 1, wherein A<sub>1</sub> is NH.
5. (Original): The compound of claim 1, wherein A<sub>1</sub> is O.
6. (Previously Amended): The compound of claim 1, wherein A<sub>2</sub> is NH.
7. (Original): The compound of claim 1, wherein A<sub>2</sub> is O.
8. (Original): The compound of claim 1, wherein G<sub>1</sub> is a C<sub>1</sub> alkyl.
9. (Amended): The compound of claim 1, wherein ~~G<sub>1</sub>~~ is -(CH<sub>2</sub>)<sub>0</sub>-.
10. (Original): The compound of claim 1, wherein G<sub>1</sub> is a C<sub>2</sub> alkyl.
11. (Original): The compound of claim 1, wherein G<sub>1</sub> is a C<sub>3</sub> alkyl.
12. (Original): The compound of claim 1, wherein G<sub>3</sub> is a C<sub>1</sub> alkyl.
13. (Original): The compound of claim 1, wherein G<sub>3</sub> is a C<sub>2</sub> alkyl.
14. (Original): The compound of claim 1, wherein G<sub>5</sub> is a C<sub>1</sub> alkyl.
15. (Original): The compound of claim 1, wherein G<sub>5</sub> is a C<sub>2</sub> alkyl.
16. (Amended): The compound of claim 1, wherein G<sub>2</sub> is ~~represented by the~~  
formula:



wherein A<sub>3</sub> is NH ~~selected from the group consisting of O, S and N~~ and A<sub>4</sub> is NH<sub>2</sub> N ~~and wherein the valencies of each O, N or S are adjusted by adding a H if needed.~~

17. (Cancelled):

18. (Amended): The compound of claim 1, wherein -NH-G<sub>2</sub> -N-G<sub>2</sub> forms a guanidino ~~containing~~ moiety.

19. (Amended): The compound of claim 1, wherein -NH-G<sub>2</sub> -N-G<sub>2</sub> forms a urea ~~containing~~ moiety.

20. (Cancelled):

21. (Cancelled):

22. (Original): The compound of claim 1, wherein G<sub>4</sub> is phenylsulfonylamino.


23. (Original): The compound of claim 1, wherein G<sub>4</sub> is phenyl.

24. (Original): The compound of claim 1, wherein G<sub>6</sub> and G<sub>7</sub> are halogens.

25. (Original): The compound of claim 1, wherein G<sub>6</sub> and G<sub>7</sub> are the same.

26. (Original): The compound of claim 1, wherein G<sub>6</sub> or G<sub>7</sub> are F.


27. (Amended): The compound of claim 1 further represented by the formula:



wherein X is selected from the group consisting of O and S;

G<sub>1</sub> and G<sub>3</sub> are C<sub>1-4</sub> alkyl chains;

G<sub>2</sub> is H or ~~selected from the group consisting of:~~



wherein A<sub>3</sub> is NH and A<sub>4</sub> is NH<sub>2</sub> or


-NH-G<sub>2</sub> forms a urea moiety ~~are individually selected from the group consisting of O, N, and S, wherein the valencies of each O, N or S are adjusted by adding a H if needed and G<sub>8</sub> is a C<sub>1-4</sub> alkyl chain;~~

wherein G<sub>4</sub> is a C<sub>5-8</sub> aryl, a C<sub>5-8</sub> arylsulfonylamino, or a C<sub>5-8</sub> arylamino; and

wherein G<sub>6</sub> and G<sub>7</sub> are individually selected from the group consisting of H, F, Cl, I, Br and a C<sub>1-4</sub> alkyl.

28. (Previously Amended): The compound of claim 27, wherein X is S.

29. (Previously Amended): The compound of claim 27, wherein X is O.
30. (Original): The compound of claim 27, wherein G<sub>1</sub> is a C<sub>1</sub> alkyl.
31. (Original): The compound of claim 27, wherein G<sub>1</sub> is a C<sub>2</sub> alkyl.
32. (Original): The compound of claim 27, wherein G<sub>3</sub> is a C<sub>1</sub> alkyl.
33. (Original): The compound of claim 27, wherein G<sub>3</sub> is a C<sub>2</sub> alkyl.
34. (Previously Amended): The compound of claim 27, wherein G<sub>2</sub> is represented by the formula:



wherein A<sub>3</sub> is NH selected from the group consisting of O, S and N and A<sub>4</sub> is NH<sub>2</sub> N and wherein the valencies of each O, N or S are adjusted by adding a H if needed.

35. (Cancelled):
36. (Amended): The compound of claim 27, wherein -NH-G<sub>2</sub> ~~-N-G<sub>2</sub>~~ forms a guanidino ~~containing~~ moiety.
37. (Amended): The compound of claim 27, wherein -NH-G<sub>2</sub> ~~-N-G<sub>2</sub>~~ forms a urea ~~containing~~ moiety.
38. (Cancelled):
39. (Cancelled):

40. (Previously Amended): The compound of claim 27, wherein G<sub>4</sub> is phenylsulfonylamino.
41. (Previously Amended): The compound of claim 27, wherein G<sub>4</sub> is phenyl.
42. (Original): A method of treating cancer comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.
43. (Original): A method of treating a tumor comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.
44. (Original): A method of treating a solid tumor comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.
45. (Original): A method of treating metastasis comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.
46. (Original): A method of inhibiting angiogenesis comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.
47. (Original): A method of inhibiting fibronectin binding comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.
48. (Original): A method of inhibiting osteopontin binding comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.
49. (Original): A method of treating foot and mouth disease comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.
50. (Original): A method of treating osteoporosis comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

51. (Original): A method of treating restenosis comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.
52. (Original): A method of treating ocular diseases comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.
53. (Original): A method of treating heart diseases comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.
54. (Original): A method of treating arthritis comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.
55. (Original): A method of treating diseases in which abnormal neovascularization occurs comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.
56. (Amended): A method of inhibiting  $\alpha_v \alpha_3$  integrins comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.
57. (Original): A method of inhibiting  $\alpha_v \beta_3$  integrin comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.
58. (Original): A pharmaceutical composition for treating cancer comprising a pharmaceutically effective amount of a compound of claim 1.
59. (Original): A pharmaceutical composition for treating tumor comprising a pharmaceutically effective amount of a compound of claim 1.
60. (Original): A pharmaceutical composition for treating solid tumor comprising a pharmaceutically effective amount of a compound of claim 1.

61. (Original): A pharmaceutical composition for treating metastasis comprising a pharmaceutically effective amount of a compound of claim 1.

62. (Original): A pharmaceutical composition for inhibiting angiogenesis comprising a pharmaceutically effective amount of a compound of claim 1.

63. (Original): A pharmaceutical composition for inhibiting fibronectin binding comprising a pharmaceutically effective amount of a compound of claim 1.

64. (Original): A pharmaceutical composition for inhibiting osteopontin binding comprising a pharmaceutically effective amount of a compound of claim 1.

65. (Original): A pharmaceutical composition for treating foot and mouth disease comprising a pharmaceutically effective amount of a compound of claim 1.

66. (Original): A pharmaceutical composition for treating osteoporosis comprising a pharmaceutically effective amount of a compound of claim 1.

67. (Original): A pharmaceutical composition for treating restenosis comprising a pharmaceutically effective amount of a compound of claim 1.

68. (Original): A pharmaceutical composition for treating ocular diseases comprising a pharmaceutically effective amount of a compound of claim 1.

69. (Original): A pharmaceutical composition for treating heart diseases comprising a pharmaceutically effective amount of a compound of claim 1.

70. (Original): A pharmaceutical composition for treating arthritis comprising a pharmaceutically effective amount of a compound of claim 1.

71. (Original): A pharmaceutical composition for treating diseases in which abnormal neovascularization occurs comprising a pharmaceutically effective amount of a compound of claim 1.

72. (Original): A pharmaceutical composition for inhibiting  $\alpha_v$  integrins comprising a pharmaceutically effective amount of a compound of claim 1.

73. (Original): A pharmaceutical composition for inhibiting  $\alpha_v\beta_3$  integrin comprising a pharmaceutically effective amount of a compound of claim 1.

74. (Previously Amended): A combination useful for the treatment of cancer comprising at least one compound of claim 1 and at least one other anticancer agent or antiangiogenic agent.

75. (Previously Amended): A combination useful for the treatment of cancer comprising at least one compound of claim 1 and at least one other anticancer agent selected from the group consisting of alkylating agents, antitumor antibiotics, antimetabolites, biological agents, hormonal agents, nitrogen mustard derivatives and plant alkaloids.